Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGFBP5 | P24593 | 6/20 | 0.43 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427587 | 1.00 | IGFBP5 (0.43) | IGFBP5IGFBP3GRM2ALOX15TDP1 | |
| SCHEMBL21873426 | 0.90 | GRM2 (0.40) | GRM2TDP1APOBEC3AAPOBEC3GL3MBTL1 | |
| SCHEMBL30428545 | 0.90 | GRM2 (0.40) | GRM2TDP1APOBEC3AAPOBEC3GL3MBTL1 | |
| SCHEMBL12803363 | 0.84 | ALOX15 (0.53) | IGFBP5IGFBP3GRM2ALOX15MEN1 | |
| SCHEMBL21935353 | 0.81 | CHRM1 (0.47) | KMT2AADORA2A | |
| SCHEMBL21873509 | 0.78 | CHRM1 (0.48) | — | |
| SCHEMBL31668977 | 0.78 | CHRM1 (0.48) | — | |
| SCHEMBL21873639 | 0.77 | BRD4 (0.37) | IGFBP5IGFBP3 | |
| SCHEMBL21873469 | 0.77 | CHRM1 (0.48) | GRM2 | |
| SCHEMBL30427840 | 0.77 | CHRM1 (0.48) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378256-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | disclosed |
| US-11236099-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3643718-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | IGFBP5 1056/4885IGFBP3 2894/4885GRM2 2865/4885 |
| US-12378256-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | IGFBP5 1056/4885IGFBP3 2894/4885GRM2 2865/4885 |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | IGFBP5 1056/4885IGFBP3 2894/4885GRM2 2865/4885 |
| US-11236099-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | IGFBP5 1056/4885IGFBP3 2894/4885GRM2 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.